| Fiscal Period | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Period End Date | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
| Cash Equivalents | 710.70 | 292.80 | 231.00 | 877.60 |
| Short Term Investments | 7,674.70 | 5,601.90 | 2,951.30 | 1,974.40 |
| Cashand Short Term Investments | 8,385.40 | 6,164.20 | 4,420.70 | 3,438.70 |
| Accounts Receivable- Trade Net | 8,029.80 | 7,248.50 | 6,676.40 | 4,964.10 |
| Total Receivables Net | 8,029.80 | 8,799.30 | 7,808.30 | 6,133.70 |
| Total Inventory | 6,355.20 | 4,867.00 | 5,088.40 | 4,541.20 |
| Other Current Assets Total | 2,034.90 | 449.80 | 351.10 | 322.60 |
| Total Current Assets | 24,805.30 | 20,425.50 | 17,782.30 | 14,550.30 |
| Property/ Plant/ Equipment Total- Gross | 1,351.00 | 15,151.40 | 14,086.30 | 12,690.70 |
| Property/ Plant/ Equipment Total- Net | 7,599.70 | 6,629.40 | 6,166.50 | 5,686.10 |
| Goodwill Net | 550.10 | 547.40 | 547.30 | 559.90 |
| Intangibles Net | 3,695.10 | 3,072.40 | 2,701.10 | 3,524.80 |
| Long Term Investments | 646.70 | 542.10 | 808.90 | 843.50 |
| Note Receivable- Long Term | 371.80 | 289.10 | 384.70 | 310.30 |
| Other Long Term Assets Total | 1,195.10 | 779.20 | 1,356.10 | 1,141.90 |
| Total Assets | 38,863.80 | 32,285.10 | 29,746.90 | 26,616.80 |
| Accounts Payable | 2,614.40 | 2,268.40 | 2,266.20 | 1,810.90 |
| Current Portof LT Debt/ Capital Leases | 1,403.00 | 480.40 | 101.70 | 86.40 |
| Other Currentliabilities Total | 5,570.60 | 2,282.40 | 2,286.10 | 1,752.10 |
| Total Current Liabilities | 9,588.00 | 8,572.10 | 9,765.80 | 8,103.80 |
| Long Term Debt | 380.00 | 0.00 | 380.00 | 380.00 |
| Capital Lease Obligations | 219.00 | 127.80 | 194.60 | 249.90 |
| Total Long Term Debt | 599.00 | 127.80 | 574.60 | 629.90 |
| Total Debt | 2,002.00 | 1,347.20 | 3,384.50 | 3,030.80 |
| Deferred Income Tax | 84.10 | 76.00 | 1.40 | 28.90 |
| Other Liabilities Total | 337.90 | 223.10 | 192.70 | 212.50 |
| Total Liabilities | 10,609.00 | 8,999.00 | 10,534.50 | 8,975.10 |
| Common Stock Total | 83.40 | 83.30 | 83.20 | 83.20 |
| Retained Earnings( Accumulated Deficit) | 28,171.40 | 22,456.10 | 18,342.80 | 16,560.40 |
| Total Equity | 28,254.80 | 23,286.10 | 19,212.40 | 17,641.70 |
| Total Liabilities Shareholders' Equity | 38,863.80 | 32,285.10 | 29,746.90 | 26,616.80 |
| Total Common Shares Outstanding | 16.65 | 16.62 | 16.60 | 16.57 |
| Tangible Book Valueper Share Common Eq | 1,441.77 | 1,183.60 | 961.93 | 818.04 |
| Cash | - | 269.50 | 1,238.40 | 586.70 |
| Prepaid Expenses | - | 145.20 | 113.80 | 114.10 |
| Accumulated Depreciation Total | - | -8,522.00 | -7,919.80 | -7,004.60 |
| Accrued Expenses | - | 2,801.90 | 2,403.60 | 2,139.90 |
| Notes Payable/ Short Term Debt | - | 739.00 | 2,708.20 | 2,314.50 |
| Additional Paid- In Capital | - | 710.90 | 670.10 | 630.80 |
| Treasury Stock- Common | - | -1,269.00 | -1,601.00 | -1,967.00 |
| Other Equity Total | - | 162.70 | 276.40 | 564.00 |
Dr Reddys Laboratories Dividend Dr Reddys Laboratories Bonus Dr Reddys Laboratories News Dr Reddys Laboratories AGM Dr Reddys Laboratories Rights Dr Reddys Laboratories Splits Dr Reddys Laboratories Board Meetings Dr Reddys Laboratories Key Metrics Dr Reddys Laboratories Shareholdings Dr Reddys Laboratories Profit Loss Dr Reddys Laboratories Cashflow Dr Reddys Laboratories Q1 Results Dr Reddys Laboratories Q2 Results Dr Reddys Laboratories Q3 Results Dr Reddys Laboratories Q4 Results
Top GainersTop LosersIndian IndicesBSE Active StocksNSE Active Stocks